Veraxa Biotech AG (VRXA) Cash Flow Statement

NASDAQ: VRXAOperating cash, capex, free cash flow and buybacks.

Where VRXA’s cash came from and went, 2025

December 31, 2025 · Swiss francs
Cash from operations
−CHF 9.9M
Capital expenditures
CHF 437,176
1,866.2% of revenue
Free cash flow
−CHF 10.3M
−44,136.9% margin
Returned to shareholders
—
Change in cash
−CHF 3.7M
cash at year-end CHF 1.6M
Borrowing: CHF 835,360BorrowingCHF 835,360Shares issued: CHF 5.8MShares issuedCHF 5.8MDrawn from cash: CHF 3.7MDrawn from cashCHF 3.7MCash used in operations: CHF 9.9MCash used in operationsCHF 9.9M · 96%Capital expenditures: CHF 437,176Capital expendituresCHF 437,176 · 4%CHF 10.3M
Cash from operations
−CHF 9.9M
Capital expenditures
−CHF 437,176
Net borrowing (repayment)
+CHF 835,360
Shares issued
+CHF 5.8M
Change in cash
−CHF 3.7M

Drawn to scale: where the cash came from and how it was used. Hover for values.

VRXA operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

VRXA cash flow trends, 2023–2025

MetricTrendThenLatestChange
Operating cash flow−CHF 7.3M2023−CHF 9.9M2025—
Capital expendituresCHF 232,3072023CHF 437,1762025+37.2%/yr
Free cash flow−CHF 7.5M2023−CHF 10.3M2025—
Stock-based compensationCHF 7.6M2023CHF 52.7M2025+163.0%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

VRXA cash flow by activity

OperatingInvestingFinancingChange in cash

VRXA net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

VRXA cash flow statement in Swiss francs

202520242023
Operating activities
Net income−CHF 66.6M−CHF 28.1M−CHF 16.5M
Depreciation & amortizationCHF 2.0MCHF 1.9MCHF 1.9M
Stock-based compensationCHF 52.7MCHF 18.3MCHF 7.6M
Change in working capitalCHF 1.2MCHF 438,095−CHF 694,326
Other non-cash itemsCHF 897,703−CHF 230,191CHF 508,033
Cash from operating activities−CHF 9.9M−CHF 7.7M−CHF 7.3M
Investing activities
Capital expenditures−CHF 437,176−CHF 120,877−CHF 232,307
Financing activities
Net borrowing (repayment)CHF 835,360CHF 0—
Shares issuedCHF 5.8MCHF 1.9MCHF 12.5M
Other financingCHF 0CHF 0CHF 0
Cash from financing activitiesCHF 6.6MCHF 1.9MCHF 12.5M
Summary
Net change in cash−CHF 3.7M−CHF 6.0MCHF 4.3M
Cash at end of periodCHF 1.6MCHF 5.4MCHF 11.4M
Free cash flow−CHF 10.3M−CHF 7.8M−CHF 7.5M
Free cash flow margin−44,136.9%——
Capex / revenue1,866.2%——

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Swiss francs as reported; data from EODHD.

VRXA cash generation

In fiscal 2025 (ended December 31, 2025), Veraxa Biotech generated -CHF 9.9 million of cash from operations and spent CHF 0.4 million on capital expenditures, leaving free cash flow of -CHF 10.3 million, −44,136.9% of revenue. Cash and equivalents fell by CHF 3.7 million over the year.

Related: VRXA income statement, VRXA balance sheet. See the VRXA stock overview for the latest quote and news.

VRXA cash flow FAQ

What is Veraxa Biotech's free cash flow?

Veraxa Biotech's free cash flow was -CHF 10.3 million in fiscal 2025: -CHF 9.9 million of operating cash flow minus CHF 0.4 million of capital expenditures It was -CHF 7.8 million a year earlier..

How much cash does Veraxa Biotech generate from operations?

Veraxa Biotech generated -CHF 9.9 million of cash from operating activities in fiscal 2025.

How much does Veraxa Biotech spend on capital expenditures?

Veraxa Biotech spent CHF 0.4 million on capital expenditures in fiscal 2025, 1,866.2% of revenue, compared with CHF 0.1 million the year before.

Biotechnology: cash flow